Wei C M, Kim C H, Miller V M, Burnett J C
Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, Minnesota 55905.
J Clin Invest. 1993 Oct;92(4):2048-52. doi: 10.1172/JCI116800.
This study reports the cardiovascular and renal actions of a novel and newly synthesized 27-amino acid peptide termed vasonatrin peptide (VNP). VNP is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). This synthetic peptide possesses the 22-amino acid structure of CNP, which is a cardiovascular selective peptide of endothelial origin and is structurally related to ANP. VNP also possesses the five-amino acid COOH terminus of ANP. The current study demonstrates both in vitro and in vivo that VNP possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP.
本研究报告了一种名为血管钠肽（VNP）的新型合成27氨基酸肽的心血管和肾脏作用。VNP是心房利钠肽（ANP）和C型利钠肽（CNP）的嵌合体。这种合成肽具有CNP的22氨基酸结构，CNP是一种内皮起源的心血管选择性肽，在结构上与ANP相关。VNP还具有ANP的五氨基酸COOH末端。当前研究在体外和体内均表明，VNP具有CNP的静脉舒张作用、ANP的利钠作用以及与ANP或CNP均无关的独特动脉舒张作用。
Zotero 插件